Allogene Therapeutics, Inc. Nonoperating Income (Expense) in USD from Q4 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Allogene Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q4 2017 to Q3 2025.
  • Allogene Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $3.5M, a 36.1% decline year-over-year.
  • Allogene Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $15.8M, a 10% increase year-over-year.
  • Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $16.1M, a 3301% increase from 2023.
  • Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $472K.
  • Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$4.88M, a 162% decline from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

Allogene Therapeutics, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $15.8M $3.5M -$1.98M -36.1% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $17.8M $5.88M +$803K +15.8% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-13
Q1 2025 $17M $5.46M +$954K +21.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-13
Q4 2024 $16.1M $994K +$1.66M Oct 1, 2024 Dec 31, 2024 10-K 2025-03-13
Q3 2024 $14.4M $5.48M +$4.77M +673% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-06
Q2 2024 $9.62M $5.07M +$3.77M +288% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 $5.85M $4.5M +$5.38M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-13
Q4 2023 $472K -$669K +$211K +24% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-13
Q3 2023 $261K $709K +$2.44M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$2.18M $1.31M +$4.98M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$7.16M -$876K -$2.28M -162% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$4.88M -$880K +$742K +45.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$5.62M -$1.73M -$1.22M -235% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-14
Q2 2022 -$4.41M -$3.67M -$3.77M -4051% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-14
Q1 2022 -$638K $1.41M +$1.22M +656% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-14
Q4 2021 -$1.86M -$1.62M +$63.7M +97.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 -$65.6M -$516K -$2.36M -128% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$63.2M $93K -$2.09M -95.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$61.2M $186K -$3.02M -94.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$58.1M -$65.4M -$68.8M -2028% Oct 1, 2020 Dec 31, 2020 10-K/A 2024-03-14
Q3 2020 $10.6M $1.84M -$2.47M -57.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $13.1M $2.18M -$2.38M -52.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $15.5M $3.2M -$1.62M -33.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $17.1M $3.39M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-23
Q3 2019 $4.31M +$25.6M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $4.56M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $4.83M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q3 2018 -$21.3M Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-21
Q4 2017 $0 Nov 30, 2017 Dec 31, 2017 10-K 2020-02-27

Allogene Therapeutics, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $16.1M +$15.6M +3301% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-13
2023 $472K +$5.35M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-13
2022 -$4.88M -$3.02M -162% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 -$1.86M +$56.3M +96.8% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-14
2020 -$58.1M -$75.2M -440% Jan 1, 2020 Dec 31, 2020 10-K/A 2024-03-14
2019 $17.1M +$35.9M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-23
2018 -$18.8M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.